Lung Adenocarcinoma: Guiding EGFR-targeted Therapy and Beyond

Modern Pathology - United Kingdom
doi 10.1038/modpathol.3801018
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.13-12 EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma

Scientific Reports
Multidisciplinary
2019English

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology
2014English

Mutation Testing for Directing Upfront Targeted Therapy and Post-Progression Combination Therapy Strategies in Lung Adenocarcinoma

Expert Review of Molecular Diagnostics
Forensic MedicineGeneticsPathologyMolecular MedicineMolecular Biology
2016English

MA27.10 EGFR-Targeted Therapy Alters the Tumor Microenvironment in EGFR-Driven Lung Tumors: Rationale for Combination Therapies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Molecularly Targeted Therapy: Imatinib and Beyond

2012English

Proteogenomic Systems Analysis Identifies Targeted Therapy Resistance Mechanisms in EGFR-mutated Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2018English

OA07.06 Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy